On the subject in the title: Secretagogues and glucose tolerance: the mechanistic concern Working notes rather than a conclusion.
Secretagogues and glucose tolerance, and specifically the version of it that the documentation does not cover. The maintained page handles the general case well and stops exactly where my question starts.
Setting out the gap in case it is a gap in the page rather than a gap in what is known.
Confirming the opening post from a second method, which matters more than confirming it from a second person.
The most useful thing anyone has posted about secretagogues and glucose tolerance in this category was a table of what had been measured and by whom. That is what I would want again.
I had written a reply contradicting the opening post and deleted it. Here is what survived.
Timing arguments in this family generally rest on the assumption that endogenous release is suppressed by circulating glucose and insulin. That is well supported; the practical protocols built on top of it are much less so.
Someone should write this up properly, and it should probably not be me.
Reading a rodent study on a secretagogue without over-extrapolating: rodent studies can show a mechanism is plausible. They cannot show magnitude of effect in humans or safety profile in humans. That gap is larger for secretagogues than for incretin agonists because the human evidence is thinner.
Take it as a starting point and not as a specification.
Two claims get bundled together under secretagogues and glucose tolerance and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal one — this is why — usually is not.
Almost every disagreement in threads like this one dissolves once you say which of the two you are making.
Post #6 is right about the mechanism and I think understates the practical bit.
Injection-site reactions are reported more often in this family than for the incretins. Whether that is the compounds or the preparations they are typically supplied in is not established.
I would want the raw data before agreeing with my own summary of it.
What would change my mind on secretagogues and glucose tolerance is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would rather say so than pretend to more.
Worth separating two things that post #8 runs together.
Research-use-only secretagogues are not approved for human use. That statement is doing real work in this subcategory, where the published evidence base is thinner than the volume of confident discussion.
I read post #7 twice before replying, because I had assumed the opposite.
Growth hormone secretagogues act on the ghrelin receptor or on the growth hormone releasing hormone receptor rather than supplying growth hormone, which is the distinction that matters for anyone reading the literature.
I am not the right person to answer the follow-up to this.
Sermorelin and the growth hormone releasing hormone analogues depend on a functioning pituitary response, which is the mechanistic reason they behave differently in different people rather than a dosing problem.
On secretagogues and glucose tolerance I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.
Counterpoint on secretagogues and glucose tolerance, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.
Everything in post #11 holds. The case it does not cover is the one I have.
Storage: these are lyophilised short peptides and are generally reasonably stable dry and considerably less so in solution. Reconstituting only what will be used within the period the supplier's own data covers is the conservative approach.
Anyone who has looked at this more carefully, please correct the record.
Narrowing post #15, because the general version has more than one answer.
Secretagogues and glucose tolerance: there is a mechanistic concern that sustained growth hormone elevation might impair glucose tolerance. The clinical relevance of this concern in practice is not well established.
That has held every time I have looked, which is not the same as always.
Agreed, and I will stop repeating the version of this I had been repeating.
A mass result for a short peptide is more discriminating than for a long one, because a single residue difference is a larger proportion of the total. That makes identity confirmation genuinely useful here.
One more thing on secretagogues and glucose tolerance that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.
The arithmetic in post #19 is right; the assumption feeding it is the part to check.
I would call the community position on secretagogues and glucose tolerance likely rather than established, and I would be comfortable defending that hedge.
Worth separating secretagogues and glucose tolerance as a question about the compound from secretagogues and glucose tolerance as a question about the documentation. They get answered by different people and only one of them is answerable here.
The arithmetic in post #20 is right; the assumption feeding it is the part to check.
Adding the boring version of secretagogues and glucose tolerance, because the interesting version keeps getting posted and the boring one is usually right.
Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.
Effects reported at the level of appetite are the most consistently described and the most mechanistically direct for the ghrelin-receptor compounds, which is not what most people are taking them for.
On balance I think that is right, and I would not bet much on it.
Evidence quality in the secretagogue literature is honestly weaker than in the incretin literature. Large randomised controlled trials are rare. Most evidence is mechanistic or from small studies. This is why this subcategory has higher sourcing standards than most.
That matches what I have seen, for whatever a single anecdote is worth.
For anyone finding this later: the short answer on secretagogues and glucose tolerance is that it depends on one thing, and the rest of the thread is people identifying which thing.
I keep a log for secretagogues and glucose tolerance specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it.
Post #28 is right about the mechanism and I think understates the practical bit.
On analysis: these are short peptides and generally straightforward chromatographically, which means a poor purity result is more likely to reflect the synthesis than the method.
Written quickly, so the reasoning may be tighter than the wording.
Why this subcategory is stricter about sourcing than most: the evidence base is weaker and that is precisely why documentation quality matters more. A supplier page that clearly identifies the compound and the purity is more valuable for secretagogues than for incretin agonists where the evidence base is stronger.
I have written this out at length because the short version keeps being misread.